Received Apr 13, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (QUADRACEL) | SANOFI PASTEUR | 3 | U8383AB | IM / RL |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 4 | 95BJ9 | IM / RL |
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | 2 | MMO530 | IM / LL |
The patient was due for DTaP and IPV vaccines. Quadracel (DTaP/IPV combination) was administered; however, it is not indicated for the patient?s age. The patient?s mother was notified and educated on potential adverse reactions, and she verbalized understanding.
none
none
none
NKDA
none